Product Pipeline
After 10 years of experiences in the development of Tucidinostat, the R&D team has independently developed novel drugs with innovative mechanisms for cancer immunotherapy---GNTbm-38 and GNTbm-TKI, both of which are essential components of combination immunotherapies and have unique and various mechanisms for regulation of tumor microenvironment. They are expected to be important for future combination therapies with immune checkpoint inhibitors or anti-PD-1/VEGF bispecific antibodies, and are anticipated to provide better cancer immunotherapy effectiveness to meet the treatment needs of patients with different advanced solid tumors.
Product Pipeline
Product and Mechanisms
Introduction to the mechanisms of action of GNTbm products under development
